Ajax Therapeutics Inc. has synthesized heterocyclic amide and urea compounds acting as tyrosine-protein kinase JAK2 inhibitors and thus reported to be useful for the treatment of cancer and myelofibrosis.
A Beijing Danatlas Pharmaceutical Technology Co. Ltd. patent describes tricyclic heterocyclic derivatives acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.
In what represents the first patenting in the name of Houston-based Neurastasis Inc., company co-founders Kirt Gill and Joe Upchurch describe a head-worn apparatus for neural stimulation that can be used to treat or augment recovery from medical conditions, particularly ischemic stroke.
Korea Institute of Radiological and Medical Sciences, Nextgen Bioscience Co. Ltd. and Yonsei University have jointly prepared purine derivative compounds acting as adenosine A3 receptor agonists reported to be useful for the treatment of pulmonary fibrosis.
Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.
Work at Sonata Therapeutics Inc. has led to the creation of phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Shenzhen Zhongge Biotechnology Co. Ltd. has patented new translation initiation factor 2B (eIF2B) activators described as potentially useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, autoimmune, eye, renal and dermatological disorders, among others.
Guangzhou Lianrui Pharmaceutical Co. Ltd. has identified benzo bicyclic compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists and reported to be useful for the treatment of diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity.
Researchers from the University of Edinburgh seek protection for an algorithm developed using artificial intelligence that could be used by doctors to diagnose heart attacks more quickly and effectively.
RSS
